OBJECTIVE: To describe the scale-up of a decentralized HIV treatment programme delivered through the primary health care system in rural KwaZulu-Natal, South Africa, and to assess trends in baseline characteristics and outcomes in the study population. METHODS: The programme started delivery of antiretroviral therapy (ART) in October 2004. Information on all patients initiated on ART was captured in the programme database and follow-up status was updated monthly. All adult patients (> or = 16 years) who initiated ART between October 2004 and September 2008 were included and stratified into 6-month groups. Clinical and sociodemographic characteristics were compared between the groups. Retention in care, mortality, loss to follow-up and virological outcomes were assessed at 12 months post-ART initiation. FINDINGS: A total of 5719 adults initiated on ART were included (67.9% female). Median baseline CD4+ lymphocyte count was 116 cells/microl (interquartile range, IQR: 53-173). There was an increase in the proportion of women who initiated ART while pregnant but no change in other baseline characteristics over time. Overall retention in care at 12 months was 84.0% (95% confidence interval, CI: 82.6-85.3); 10.9% died (95% CI: 9.8-12.0); 3.7% were lost to follow-up (95% CI: 3.0-4.4). Mortality was highest in the first 3 months after ART initiation: 30.1 deaths per 100 person-years (95% CI: 26.3-34.5). At 12 months 23.0% had a detectable viral load (> 25 copies/ml) (95% CI: 19.5-25.5). CONCLUSION: Outcomes were not affected by rapid expansion of this decentralized HIV treatment programme. The relatively high rates of detectable viral load highlight the need for further efforts to improve the quality of services.
OBJECTIVE: To describe the scale-up of a decentralized HIV treatment programme delivered through the primary health care system in rural KwaZulu-Natal, South Africa, and to assess trends in baseline characteristics and outcomes in the study population. METHODS: The programme started delivery of antiretroviral therapy (ART) in October 2004. Information on all patients initiated on ART was captured in the programme database and follow-up status was updated monthly. All adult patients (> or = 16 years) who initiated ART between October 2004 and September 2008 were included and stratified into 6-month groups. Clinical and sociodemographic characteristics were compared between the groups. Retention in care, mortality, loss to follow-up and virological outcomes were assessed at 12 months post-ART initiation. FINDINGS: A total of 5719 adults initiated on ART were included (67.9% female). Median baseline CD4+ lymphocyte count was 116 cells/microl (interquartile range, IQR: 53-173). There was an increase in the proportion of women who initiated ART while pregnant but no change in other baseline characteristics over time. Overall retention in care at 12 months was 84.0% (95% confidence interval, CI: 82.6-85.3); 10.9% died (95% CI: 9.8-12.0); 3.7% were lost to follow-up (95% CI: 3.0-4.4). Mortality was highest in the first 3 months after ART initiation: 30.1 deaths per 100 person-years (95% CI: 26.3-34.5). At 12 months 23.0% had a detectable viral load (> 25 copies/ml) (95% CI: 19.5-25.5). CONCLUSION: Outcomes were not affected by rapid expansion of this decentralized HIV treatment programme. The relatively high rates of detectable viral load highlight the need for further efforts to improve the quality of services.
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Rishikesh P Dalal; Catherine Macphail; Mmabatho Mqhayi; Jeff Wing; Charles Feldman; Matthew F Chersich; Willem D F Venter Journal: J Acquir Immune Defic Syndr Date: 2008-01-01 Impact factor: 3.731
Authors: Catherine Orrell; Guy Harling; Stephen D Lawn; Richard Kaplan; Matthew McNally; Linda-Gail Bekker; Robin Wood Journal: Antivir Ther Date: 2007
Authors: Andrew M Abaasa; Jim Todd; Kenneth Ekoru; Joan N Kalyango; Jonathan Levin; Emmanuel Odeke; Charles A S Karamagi Journal: BMC Health Serv Res Date: 2008-11-20 Impact factor: 2.655
Authors: Frank Tanser; Victoria Hosegood; Till Bärnighausen; Kobus Herbst; Makandwe Nyirenda; William Muhwava; Colin Newell; Johannes Viljoen; Tinofa Mutevedzi; Marie-Louise Newell Journal: Int J Epidemiol Date: 2007-11-12 Impact factor: 7.196
Authors: Krisda Chaiyachati; Lisa R Hirschhorn; Frank Tanser; Marie-Louise Newell; Till Bärnighausen Journal: AIDS Patient Care STDS Date: 2011-01-26 Impact factor: 5.078
Authors: Catherine E Oldenburg; Till Bärnighausen; Frank Tanser; Collins C Iwuji; Victor De Gruttola; George R Seage; Matthew J Mimiaga; Kenneth H Mayer; Deenan Pillay; Guy Harling Journal: Clin Infect Dis Date: 2016-09-29 Impact factor: 9.079
Authors: James H McMahon; Julian H Elliott; Silvia Bertagnolio; Rachel Kubiak; Michael R Jordan Journal: Bull World Health Organ Date: 2013-02-21 Impact factor: 9.408
Authors: Jacob Bor; Till Bärnighausen; Colin Newell; Frank Tanser; Marie-Louise Newell Journal: Trop Med Int Health Date: 2011-05-26 Impact factor: 2.622
Authors: Daniel Cobos Muñoz; Paloma Merino Amador; Laura Monzon Llamas; David Martinez Hernandez; Juana Maria Santos Sancho Journal: Int J Public Health Date: 2016-08-29 Impact factor: 3.380
Authors: Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731